 Connection
Bradford Siegele to Treatment Outcome
This is a "connection" page, showing publications Bradford Siegele has written about Treatment Outcome.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.090 |
|
|
|
-
Siegele BJ, Shilo K, Chao BH, Carbone DP, Zhao W, Ioffe O, Franklin WA, Edelman MJ, Aisner DL. Epidermal growth factor receptor (EGFR) mutations in small cell lung cancers: Two cases and a review of the literature. Lung Cancer. 2016 May; 95:65-72.
Score: 0.041
-
Winters AC, Minhajuddin M, Stevens BM, Major A, Bosma G, Abbott D, Miltgen N, Yuan J, Treece AL, Siegele BJ, Ewalt MD, Gutman JA, Jordan CT, Pollyea DA. Multi-gene measurable residual disease assessed by digital polymerase chain reaction has clinical and biological utility in acute myeloid leukemia patients receiving venetoclax/azacitidine. Haematologica. 2024 06 01; 109(6):1766-1778.
Score: 0.018
-
Murphy L, Siegele B, Carstens B, Hartman L, Faulk K. A pediatric case of KMT2A-rearranged B-lymphoblastic lymphoma treated with high-risk therapy. Leuk Lymphoma. 2024 06; 65(6):843-847.
Score: 0.018
-
Winters AC, Gutman JA, Purev E, Nakic M, Tobin J, Chase S, Kaiser J, Lyle L, Boggs C, Halsema K, Schowinsky JT, Rosser J, Ewalt MD, Siegele B, Rana V, Schuster S, Abbott D, Stevens BM, Jordan CT, Smith C, Pollyea DA. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. Blood Adv. 2019 10 22; 3(20):2911-2919.
Score: 0.013
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|